{
    "Trade/Device Name(s)": [
        "DiaSorin LIAISON\u00ae VZV IgG",
        "LIAISON\u00ae VZV IgG"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K061820",
    "Predicate Device Reference 510(k) Number(s)": [
        "K981867"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFY"
    ],
    "Summary Letter Date": "February 13, 2007",
    "Summary Letter Received Date": "February 16, 2007",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3900"
    ],
    "Regulation Name(s)": [
        "Varicella-zoster virus Serological Reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "serology"
    ],
    "Analyte(s)": [
        "Varicella-zoster virus IgG"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescence immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Qualitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON\u00ae VZV IgG assay for qualitative detection of VZV IgG antibodies in serum using CLIA technology on the LIAISON\u00ae Analyzer.",
    "Indications for Use Summary": "Aid in the determination of previous infection with varicella-zoster virus by qualitative detection of specific IgG antibodies to VZV in human serum.",
    "fda_folder": "Microbiology"
}